Hikma Pharmaceuticals (OTCMKTS:HKMPF) Stock Jumps 4.9% – Still a Buy?

Hikma Pharmaceuticals Plc (OTCMKTS:HKMPF) shot up 4.9% during mid-day trading on Monday. The company traded as high as $22.1350 and last traded at $22.1350. 115 shares changed hands during mid-day trading, a decline of 93% from the average session volume of 1,668 shares. The stock had previously closed at $21.10.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on the stock. Barclays raised shares of Hikma Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Tuesday, September 8th. Citigroup reissued a “buy” rating on shares of Hikma Pharmaceuticals in a research note on Wednesday, August 12th. One analyst has rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy”.

Hikma Pharmaceuticals Trading Up 5.1%

The business has a 50-day moving average of $21.76 and a 200-day moving average of $20.28.

Hikma Pharmaceuticals Company Profile

Hikma Pharmaceuticals PLC is a multinational pharmaceutical company that develops, manufactures and markets a broad range of medicines. Its portfolio includes generic, branded and specialty products, as well as injectable medicines used in hospitals and other healthcare settings. The company serves areas such as respiratory, pain management, anti-infective, oncology and cardiovascular care.

Hikma operates through three principal businesses: Injectables, Generics and Branded Medicines. Its injectables business supplies a range of products to hospitals and healthcare providers, while its generics business focuses on prescription medicines, including complex products.